相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。RhoGTPases and p53 are involved in the morphological appearance and interferon-α response of hairy cells
B Chaigne-Delalande et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma
JP Delord et al.
ANNALS OF ONCOLOGY (2005)
WWOX gene restoration prevents lung cancer growth in vitro and in vivo (Publication with Expression of Concern. See vol. 114, 2017)
M Fabbri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells
J Mazières et al.
EXPERIMENTAL CELL RESEARCH (2005)
Loss of RhoB expression in human lung cancer progression
J Mazieres et al.
CLINICAL CANCER RESEARCH (2004)
Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes
IA McNeish et al.
GENE THERAPY (2004)
A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer
JK Wolf et al.
GYNECOLOGIC ONCOLOGY (2004)
Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status
SR Quist et al.
CANCER GENE THERAPY (2004)
Akt mediates ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis
K Jiang et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line
SW Wang et al.
ONCOGENE (2003)
Why did p53 gene therapy fail in ovarian cancer?
AG Zeimet et al.
LANCET ONCOLOGY (2003)
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention
F Chang et al.
LEUKEMIA (2003)
Control of vesicular trafficking by Rho GTPases
M Symons et al.
CURRENT BIOLOGY (2003)
Phase I trial of intraperitoneal injection of the E1B-55-kd-Gene -: Deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer
PA Vasey et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
The expression of Rho proteins decreases with human brain tumor progression: Potential tumor markers
MA Forget et al.
CLINICAL & EXPERIMENTAL METASTASIS (2002)
RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells
AX Liu et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity
BB Wolf et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage
AX Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors
AX Liu et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice
Z Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Ras-related GTPase RhoB forces alkylation-induced apoptotic cell death
G Fritz et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
分享论文
